Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 12, 2025
- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -
Read more at globenewswire.comNASDAQ:DRTSW (5/30/2025, 8:00:01 PM)
0.21
-0.04 (-16%)
NASDAQ:DRTS (5/30/2025, 8:00:01 PM)
2.985
-0.02 (-0.5%)
Find more stocks in the Stock Screener
